anti-cancer drugs

Show results for

Unknown (6405)
Transcriptomics (655)
Genomics (500)
Proteomics (132)
Clinical (61)
Metabolomics (26)
Other (15)
Models (12)
Methylation profiling (7)
Genomic (6)
Multiomics (2)

Organisms

Homo sapiens (641)
Mus musculus (180)
Rattus norvegicus (10)
synthetic construct (3)
Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 (2)
Campylobacter jejuni (2)
Danio rerio (2)
Schizosaccharomyces pombe (2)
Mus (1)
Agaricus bisporus (1)
Saccharomyces cerevisiae BY4741 (1)
Helicobacter pylori 26695 (1)
Pimephales promelas (1)
Populus x canadensis (1)
Papio anubis (1)
Bemisia tabaci (1)
Schizosaccharomyces pombe 972h- (1)
Pan troglodytes (1)
Mesocricetus auratus (1)
Oncorhynchus mykiss (1)
Bos taurus (1)
Heterocephalus glaber (1)
Caenorhabditis elegans (1)
Candida albicans (1)
Arabidopsis thaliana (1)
Betapolyomavirus hominis (1)
Betapolyomavirus macacae (1)
Cytomegalovirus (1)
Drosophila melanogaster (1)
Human alphaherpesvirus 1 (1)

Organisms

Homo sapiens (259)
Mus musculus (87)
Rattus norvegicus (2)
Nothapodytes nimmoniana (1)
Nostoc sp. CALU 546 (1)
Saccharomyces cerevisiae (1)
human gut metagenome (1)
Arabidopsis thaliana (1)
Staphylococcus aureus (1)
Drosophila melanogaster (1)

Repository

ENA (426)
biostudies-arrayexpress (412)
geo (328)
pride (75)
EGA (26)
MetaboLights (26)
MassIVE (22)
BioModels (11)
jPOST (9)
iProX (8)
dbGaP (6)
LINCS (2)
Cell Collective (1)
EVA (1)
PanoramaPublic (1)
PAXDB (1)

Tissue

Cell culture (28)
Epithelial cell (7)
Permanent cell line cell (6)
Blood (3)
Brain (2)
Cell suspension culture (2)
Colon (2)
Embryonic fibroblast (2)
Embryonic stem cell (2)
Fibroblast (2)
Lung (2)
Malignant cell (2)
Soft tissue sarcoma cell line (2)
Ascites tumor cell (1)
B cell (1)
Blood plasma (1)
Breast (1)
Breast cancer cell line (1)
Cell line cell (1)
Colon epithelial cell (1)
Colorectal adenocarcinoma cell line (1)
Early embryonic cell (1)
Embryonic fibroblast cell line (1)
Epithelial cell of cervix (1)
Epithelial cell of esophagus (1)
Epithelial cell of prostate (1)
Esophageal epithelial cell (1)
HeLa cell (1)
Hepatocyte (1)
T cell (1)

Disease

Colorectal Neoplasms (39)
Breast cancer (12)
Neoplasms (5)
Carcinoma (4)
Acute leukemia (4)
Colon cancer (4)
Mammary tumor (2)
Colorectal cancer (2)
Cervix carcinoma (2)
Disease free (2)
Cancer (1)
Glioblastoma multiforme (1)
Small cell cancer (1)
HPV positive (1)
Renal cancer (1)
Primary tumor (1)
Serous ovarian cancer (1)
Reference (1)
Normal (1)
Advanced breast cancer (1)
Advanced colorectal cancer (1)
Colonic Neoplasms (1)
Colorectal cancer liver metastases (1)
Glioblastoma (1)
Leukemia, Lymphoid (1)
Liver Neoplasms (1)
Melanoma (1)
Neoplasm Metastasis (1)
Ovarian Neoplasms (1)
Rectal Neoplasms (1)

Technology Type

Mass Spectrometry (75)
Shotgun proteomics (50)
Mass spectrometry (19)
Bottom-up proteomics (12)
Affinity purification coupled with mass spectrometry proteomics (11)
Mass spectrometry assay (6)
Gel-based experiment (6)
Data-dependent acquisition (5)
Data-independent acquisition (5)
Illumina HiSeq 2000 (3)
Fluorescence imaging (2)
Fluorescence intensity (2)
DiaPASEF (2)
Immunopeptidomics (2)
SWATH MS (2)
ILLUMINA, Illumina HiSeq 2500 (1)
Illumina HiSeq 2500, ILLUMINA (1)
Illumina HiSeq 4000, ILLUMINA (1)
NMR spectroscopy (1)
Mass spectrometry imaging (1)
SRM/MRM (1)
Top-down proteomics (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (9)
Illumina NovaSeq 6000 (8)
Orbitrap Fusion Lumos (7)
NextSeq 500 (5)
Q Exactive (5)
Illumina HiSeq 4000 (4)
Illumina HiSeq 2500 (3)
Illumina HiSeq 2000 (3)
LTQ Orbitrap Elite (3)
HiSeq X Ten (2)
Orbitrap Eclipse (2)
Q Exactive HF (2)
Q Exactive HF-X (2)
Agilent 2100 Bioanalyzer, Applied Biosystems 7900HT Sequence Detection System, Illumina TruSeq Small RNA Sample Preparation Kit (1)
RNeasy mini Kit, Ribo-Zero Human/Mouse/Rat kit (1)
MoFlo Legacy cell sorter (Beckman Coulter) (1)
PC (1)
Agilent 2100 Bioanalyzer (1)
GenePix 4000B [Axon Instruments] (1)
NextSeq 1000 (1)
Illumina NovaSeq X (1)
NextSeq 2000 (1)
Illumina HiSeq 1000 (1)
NextSeq 550 (1)
Illumina HiSeq 3000 (1)
MGISEQ-2000 (1)
LTQ Orbitrap (1)
LTQ Orbitrap Velos (1)
Orbitrap Fusion (1)
Xevo G2 Q-Tof (1)

Publication Date

2013 (81)
2025 (79)
2015 (72)
2024 (63)
2021 (61)
2010 (56)
2012 (53)
2014 (51)
2022 (50)
2023 (48)
2020 (39)
2016 (35)
2026 (33)
2008 (32)
2018 (28)
2019 (27)
2011 (27)
2017 (22)
2009 (17)
2007 (11)
2006 (4)
2004 (1)
2002 (1)

UNIPROT ID/AC

O70201 (1)
P70677 (1)
Q9JIQ3 (1)
6PGL_HELPY (1)
85962.C694_00040 (1)
85962.C694_00275 (1)
85962.C694_00510 (1)
85962.C694_00935 (1)
85962.C694_01080 (1)
85962.C694_01205 (1)
85962.C694_02750 (1)
85962.C694_03200 (1)
85962.C694_03205 (1)
85962.C694_03530 (1)
85962.C694_03705 (1)
85962.C694_03715 (1)
85962.C694_03730 (1)
85962.C694_04635 (1)
85962.C694_04640 (1)
85962.C694_05100 (1)
85962.C694_05145 (1)
85962.C694_05150 (1)
85962.C694_05210 (1)
85962.C694_05650 (1)
85962.C694_05655 (1)
85962.C694_05750 (1)
85962.C694_05755 (1)
85962.C694_06925 (1)
85962.C694_06985 (1)
85962.C694_07065 (1)

CHEBI ID

CHEBI:16027 (5)
CHEBI:15603 (4)
CHEBI:15741 (4)
CHEBI:15422 (3)
CHEBI:15846 (3)
CHEBI:16467 (3)
CHEBI:144829 (2)
CHEBI:15379 (1)
CHEBI:15763 (1)
CHEBI:15927 (1)
CHEBI:16134 (1)
CHEBI:16171 (1)
CHEBI:16300 (1)
CHEBI:16474 (1)
CHEBI:16675 (1)
CHEBI:16828 (1)
CHEBI:16946 (1)
CHEBI:16960 (1)
CHEBI:17111 (1)
CHEBI:17154 (1)
CHEBI:17380 (1)
CHEBI:18009 (1)
CHEBI:18050 (1)
CHEBI:18304 (1)
CHEBI:18361 (1)
CHEBI:18367 (1)
CHEBI:30249 (1)
CHEBI:32544 (1)
CHEBI:36559 (1)
CHEBI:68494 (1)

Metabolite Name

Glycerophosphocholine (5)
4-Guanidinobutanoic acid (4)
ADP (4)
Pseudouridine (4)
22-Acetylpriverogenin B (3)
4-Methylcatechol (3)
AMP (3)
Acetylcholine (3)
Adenosine (3)
Adipic acid (3)
Creatine (3)
Cuminaldehyde (3)
Hypoxanthine (3)
Indoleacrylic acid (3)
L-Isoleucine (3)
L-Threonine (3)
Lactate (3)
N-Formyl-L-methionine (3)
Pyroglutamic acid (3)
Simmondsin (3)
Spermidine (3)
Succinate (3)
Taurine (3)
Vulgaxanthin I (3)
Xanthine (3)
(1x,2x)-Guaiacylglycerol 3-glucoside (2)
(2S,4S)-Pinnatanine (2)
(4S,6R)-p-Mentha-1,8-diene-6,7-diol 7-glucoside (2)
(S)-2-Acetamido-3-(4-chlorophenyl)propanoic acid (2)
(S)-Homostachydrine (2)

First Public Date

2025 (58)
2024 (58)
2014 (46)
2021 (43)
2022 (41)
2023 (39)
2026 (33)
2020 (33)
2019 (18)
2017 (17)
2018 (15)
2016 (10)
2015 (10)
2013 (5)

Modelling Approach

Ordinary differential equation model (10)
Mathematical model (1)

Study status

Completed (20)
Recruiting (19)
Terminated (9)
Not provided (8)
Active, not recruiting (3)
Not yet recruiting (1)
Withdrawn (1)

Lab affiliation

Cancer Science Institute of Singapore (CSI), National University of Singapore (NUS) (3)
Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm 17177, Sweden (2)
1 - College of Pharmacy, University of Sharjah, Sharjah 2 - Sharjah Institute for Medical Research, University of Sharjah, Sharjah (1)
Additional Professor, Deptt. of Medical Oncology (Lab), Dr BRAIRCH, AIIMS, New Delhi (1)
Barts Cancer Institute. Queen Mary University of London (1)
Biological Mass Spectrometry Lab, Department of Translational Medicine (DiMeT),Center for Translational Research on Autoimmune & Allergic Diseases - CAAD, University of Piemonte Orientale Corso Trieste 15/A, 28100, Novara, Italy. (1)
Biomedical Research in Cancer Stem Cells Group,Pathology Department, Collserola Building, Lab 205,Vall d'Hebron Research Institute (VHIR, Passeig Vall d'Hebron 119-129,Barcelona 08035, Spain. Tel: +34-93-489-4169 FAX: +34-93-274-6708 (1)
Biomolecular Mass Spectrometry and Proteomics, University Utrecht, Utrecht, The Netherlands (1)
Bioscience Institute,Faculty for Medical Sciences at Newcastle University. Newcastle-Upon-Tyne United Kingdom NE24HH (1)
CAS Key Laboratory of Experimental Marine Biology & Center of Deep Sea Research, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, China (1)
CRUK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK. (1)
Canary Center at Stanford For Cancer Early Detection Department of Radiology School of Medicine Stanford University (1)
Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK (1)
Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Garching b. München 85747, Germany; Chair of Organic Chemistry II, Technische Universität München, Garching b. München 85747, Germany (1)
Chemistry Institute, LADETEC, Proteomics Laboratory, UFRJ, RJ, Brazil. (1)
China State Institute of Pharmaceutical Industry (1)
Chinese Academy of Sciences Shanghai Institute of Materia Medica (1)
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA (1)
Department of Biochemistry, Biophysics and General Pathology, University of Campania “Luigi Vanvitelli”, Vico L. De Crecchio 7, 80138 Napoli, IT (1)
Department of Biology, IISER Pune (1)
Department of Biology, Technion - Israel Institute of Technology, Haifa, Israel (1)
Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA. (1)
Department of General, Visceral- and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany (1)
Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany (1)
Department of Infection Control, Qilu Hospital, Shandong University, Jinan, Shandong, People’s Republic of China (1)
Department of Innovative Technologies in Medicine & Dentistry, University of "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy (1)
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden (1)
Department of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, Cologne, D-50931, Germany Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, SE-17177, Sweden Max Planck Institute for Biology of Ageing - Karolinska Institutet Laboratory, Karolinska Institutet, 171 77 Stockholm, Sweden (1)
Department of Pediatric Oncology Linde Program in Cancer Chemical Biology Dana-Farber Cancer Institute Boston, MA 02215 USA (1)
Department of Pharmacology, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC USA (1)

Keyword

Bevacizumab (10)
Fluorouracil (10)
Irinotecan (9)
Leucovorin (8)
Oxaliplatin (7)
Antibodies (5)
Antibodies, Monoclonal (5)
Cetuximab (5)
Antineoplastic Agents, Immunological (4)
Capecitabine (4)
Immunoglobulins (4)
Levoleucovorin (4)
Nivolumab (4)
Adult (3)
Camptothecin (3)
Molecular Targeted Therapy (3)
Panitumumab (3)
Pembrolizumab (3)
Precision Medicine (3)
Rare (3)
Trastuzumab (3)
Tumour-agnostic (3)
Antineoplastic Agents (2)
Calcium (2)
Calcium, Dietary (2)
Celecoxib (2)
Colorectal (2)
Immune Checkpoint Inhibitors (2)
Ipilimumab (2)
Metastatic (2)

IsPrivate

False (11)

Submitter Keywords

Immuno-oncology (4)

Classification

bacteria (1)

Modification

2x(15)N labeled L-lysine (1)
4x(15)N labeled L-arginine (1)

Study type

Transcription profiling by array (302)
Interventional (53)
RNA-seq of coding RNA (42)
Proteomic profiling by array (15)
ChIP-seq (13)
Comparative genomic hybridization by array (8)
Observational (7)
Unknown experiment type (4)
ChIP-chip by tiling array (4)
Methylation profiling by array (4)
Other (3)
RNA-seq of coding RNA from single cells (3)
Human - High-throughput sequencing (2)
Genotyping by array (2)
Transcription profiling by RT-PCR (2)
RNA-seq of total RNA (2)
Cell line - One-color microarray (1)
High-throughput sequencing (1)
Cell line - High-throughput sequencing (1)
ChIP-chip by array (1)
MicroRNA profiling by array (1)
Methylation profiling by high throughput sequencing (1)
Observational patient registry (1)

Release Date

2022 (884)
2023 (806)
2021 (729)
2020 (601)
2024 (536)
2025 (494)
2019 (425)
2018 (407)
2017 (333)
2016 (331)
2015 (315)
2014 (252)
2013 (189)
2012 (143)
2010 (112)
2011 (97)
2009 (44)
2026 (42)
2008 (37)
2007 (15)
2006 (9)
2004 (4)
2005 (3)
2003 (3)
1999 (3)
2002 (1)

Location

United States (25)
China (10)
United Kingdom (8)
Italy (5)
France (4)
Denmark (3)
Belgium (2)
Canada (2)
Spain (2)
Sweden (2)
Taiwan (2)
Australia (1)
Egypt (1)
Ireland (1)
Israel (1)
Japan (1)

Previous page
1 / 782
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 782
Next page

Sort by:

Relevance

Page size

Non-steroidal Anti-inflammatory Drugs Decrease E2F1 Expression and Inhibit Cell Growth in Ovarian Cancer Cells

Epidemiological studies have shown that the regular use of non-steroidal anti-inflammatory (NSAIDs) drugs is associated with a reduced risk of various cancers. In addition, in vitro and experiments in mouse models have demonstrated that NSAIDs decrease tumor initiation and/or progression of several ...

ORGANISM(S): Homo sapiens

2014-06-20 | E-GEOD-45052 | biostudies-arrayexpress

Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs (Murine and human plasma quantitative L-arginine and methylarginines UPLC-MS/MS assay)

BACKGROUND: Large-scale, placebo-controlled trials established that nonsteroidal anti-inflammatory drugs confer a cardiovascular hazard: this has been attributed to depression of cardioprotective products of cyclooxygenase (COX)-2, especially prostacyclin. An alternative mechanis...

2019-08-22 | MTBLS685 | MetaboLights

Biological Effects of Amphiphilic Copolymer Nanoparticle-Encapsulated Multi-target Chemotherapeutic Drugs on MCF-7 Human Breast Cancer Cells

INTRODUCTION: Amphiphilic copolymer nanoparticle-encapsulated multi-target chemotherapeutic drugs have attracted considerable attention due to their favorable drug efficiency and potential application prospect. Studies have shown that an amphiphilic copolymer, methoxypoly(ethylene glycol)-poly(lacti...

2018-05-03 | MTBLS430 | MetaboLights

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Glioblastoma, the most aggressive primary brain cancer, has dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we here syste...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

MSV000090357 | MassIVE

Chemical profiling of the genome with anti-cancer drugs defines target specificities

Many anti-cancer drugs induce DNA breaks to eliminate tumor cells. The anthracycline topoisomerase II inhibitors can also evict histones. We performed a genome-wide high-resolution mapping of chemotherapeutic effects of various topoisomerase I and II inhibitors. We show that different drugs target d...

ORGANISM(S): Homo sapiens

2015-05-10 | E-GEOD-60395 | biostudies-arrayexpress

Anti-cancer drugs curaxins target the 3D genome organization [HiC]

PRJNA482566 | ENA

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients.

Not available

S-EPMC9760465 | biostudies-literature

Anti-cancer drugs curaxins target the 3D genome organization [ChIP-seq]

PRJNA505308 | ENA

Identification of miRNAs that mediate protective function of anti-cancer drugs during white matter ischemic injury

PRJNA720106 | ENA

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [umi]